Cassava Sciences raises over $125M from warrant exercises; ~5.7M shares at $22

FILANA THERAPEUTICS, INC.

Gross proceeds over $125M from cash exercises of warrants; ~5.7M common shares issued at $22.00 per share.
Net proceeds estimated at over $123M after advisory fees and expenses.
Proceeds to fund working capital and continued development of Alzheimer's drug simufilam.
Warrants distributed to shareholders, last exercise deadline May 6, 2024; remaining warrants redeemed at $0.001 each.
B. Dyson Capital Advisors acted as exclusive financial advisor on the warrant distribution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.